Literature DB >> 352379

Double-blind trial of indoramin in digital artery disease.

P Robson, V Pearce, A C Antcliff, M Hamilton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 352379      PMCID: PMC1429396          DOI: 10.1111/j.1365-2125.1978.tb01688.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Autonomic blocking properties of Wy 21901.

Authors:  B J Alps; M Hill; E S Johnson; A B Wilson
Journal:  Br J Pharmacol       Date:  1970-09       Impact factor: 8.739

2.  The evaluation of the alpha-adrenoceptor blocking action of indoramin, phentolamine and thymoxamine on the rat and guinea-pig isolated mesenteric vasculature and aortic spiral preparations.

Authors:  M G Collis; B J Alps
Journal:  J Pharm Pharmacol       Date:  1973-08       Impact factor: 3.765

3.  The effect of parenteral indoramin on peripheral blood flow in patients with Raynaud's disease or atherosclerosis associated with intermittent claudication.

Authors:  C M Fares; J C Milliken
Journal:  Curr Med Res Opin       Date:  1974       Impact factor: 2.580

4.  A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.

Authors:  A C Antcliff; J Bouhoutsos; P Martin; T Morris
Journal:  Angiology       Date:  1974-05       Impact factor: 3.619

5.  Quantitative analysis on isolated organs of the autonomic blocking properties of indoramin hydrochloride (Wy 21901).

Authors:  B J Alps; M Hill; E S Johnson; A B Wilson
Journal:  Br J Pharmacol       Date:  1972-01       Impact factor: 8.739

  5 in total
  1 in total

Review 1.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.